Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Article first published online: 16 AUG 2012
© 2012 BJU International
Volume 111, Issue 4, pages 672–682, April 2013
How to Cite
Bennett, H. L., Stockley, J., Fleming, J. T., Mandal, R., O'Prey, J., Ryan, K. M., Robson, C. N. and Leung, H. Y. (2013), Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?. BJU International, 111: 672–682. doi: 10.1111/j.1464-410X.2012.11409.x
- Issue published online: 2 APR 2013
- Article first published online: 16 AUG 2012
Fig. S1. Western blot analysis for AR and PSA expression in LNCaP cells after 10 μm bicalutamide (bical) treatment.
Fig. S2. Representative frequency distribution of cathepsin D+ lysosomes in pixels, measured from cells maintained in 10 μm bicalutamide for the indicated time points.
Fig. S3. Representative confocal images of cells maintained in bicalutamide as described in supplementary Figure 2 and stained with cathepsin D antibody and DAPI. Scale bar, 20 nm.
Fig. S4. The average size of cathepsin D+ lysosomes in cells maintained in FBS with vehicle or bicalutamide (bical) for 96 h. In all, 15–25 cells per condition per experiment were analysed, n = 3, error bars indicate sem, **P < 0.01.
Table S1 GI50 values for docetaxel treatment.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.